Ditchcarbon
  • Customers
  1. Organizations
  2. Novartis Pharma AG
Public Profile
Pharmaceutical Preparation Manufacturing
CH
updated 5 months ago

Novartis Pharma AG

Company website

Novartis Pharma AG, commonly referred to as Novartis, is a leading global healthcare company headquartered in Switzerland (CH). Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in innovative pharmaceuticals and generics, Novartis focuses on areas such as oncology, cardiology, immunology, and neuroscience. The company is renowned for its commitment to research and development, producing unique therapies that address unmet medical needs. With a robust portfolio of patented medications and a significant market position, Novartis has achieved numerous accolades, including recognition for its contributions to advancing healthcare and improving patient outcomes worldwide.

DitchCarbon Score

How does Novartis Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

100

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Novartis Pharma AG's score of 100 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.

84%

Let us know if this data was useful to you

Novartis Pharma AG's reported carbon emissions

Inherited from Novartis AG

As of the latest available data, Novartis Pharma AG does not report specific carbon emissions figures, indicating a lack of detailed emissions data for the most recent year. However, it is important to note that Novartis Pharma AG is a current subsidiary of Novartis AG, which may influence its climate commitments and reporting. Novartis AG has established various climate initiatives and commitments that cascade down to its subsidiaries, including Novartis Pharma AG. These initiatives include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all aimed at enhancing sustainability and reducing carbon footprints across their operations. While specific reduction targets for Novartis Pharma AG are not detailed, the overarching commitments from Novartis AG suggest a strategic focus on climate action and emissions reduction. The company is actively engaged in efforts to align with global climate goals, although specific metrics and targets for Novartis Pharma AG remain unspecified. In summary, while Novartis Pharma AG currently lacks specific emissions data, it benefits from the climate commitments and initiatives of its parent company, Novartis AG, which are designed to drive sustainability and reduce carbon emissions across its operations.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201020112012201320142016201920202021202220232024
Scope 1
583,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
-
-
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
922,000,000
0,000,000,000
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 3
-
-
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Novartis Pharma AG's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Novartis Pharma AG is in CH, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Novartis Pharma AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Abbvie

US
•
Pharmaceutical Preparation Manufacturing
Updated about 10 hours ago

Codex

HU
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated about 10 hours ago

Genzyme Corporation, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated about 10 hours ago

Johnson & Johnson Innovative Medicine

US
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250804.3
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy